Compare BioNano Genomics Inc (BNGO) vs Lufax Holding Ltd (LU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Lufax Holding Ltd — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Lufax Holding Ltd trades at $1.55 (market cap $2.41B). The key difference: Lufax Holding Ltd is far larger — about 176.4× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | LU | |
|---|---|---|
Market Cap | $13.66M | $2.41B |
Sector | Health | Technology |
52-Week High | $4.92 | $4.40 |
52-Week Low | $1.06 | $1.23 |
Enterprise Value | $16.26M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Lufax Holding Ltd (LU) trades at $1.53, down 7.83% in the last session, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported a net loss of $2.1 billion on $23.1 billion revenue in 2025, with negative profitability metrics including -9.08% net margin and -2.6% ROE. Recent news highlights board changes and multiple class-action lawsuits filed against the company alleging securities fraud during the April 2023-January 2025 period.
Despite 69% analyst buy ratings, Lufax faces significant fundamental challenges with consistent earnings misses and legal uncertainties. The stock's low P/S (0.39) and P/B (0.11) ratios suggest potential value, but ongoing losses and litigation risks outweigh near-term upside potential. Investors should focus on management's ability to stabilize operations amid the legal overhang.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Lufax Holding Ltd
Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →
